Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090539 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
A Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06090539 is a Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 308 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT06090539, a Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Rituximab
- DRUG BMS-986458
- DRUG Glofitamab/Obinutuzumab
Study Locations (20)
Other
- CHU SAINT ELOI - Departement Hematologie Clinique - Montpellier
- Hôpital Saint-Louis - Paris
- Institut Claudius Regaud - Toulouse
Florida
- Local Institution - 0068 - Jacksonville
- Local Institution - 0027 - Tampa
New York
- Local Institution - 0047 - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic in Arizona - Phoenix - Phoenix
California
- City of Hope Comprehensive Cancer Center - Duarte
Kansas
- Local Institution - 0014 - Fairway
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic in Rochester, Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2023-12-29 |
| Est. Completion | 2028-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06090539
The ClinicalTrials.gov registry entry for NCT06090539 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Mosunetuzumab is the first listed.
NCT06090539 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06090539 about?
NCT06090539 is a clinical study titled "A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas". The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in pa...
What is the current status of trial NCT06090539?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 308 participants. The study started on 2023-12-29. Estimated completion is 2028-10-28.
What conditions does trial NCT06090539 study?
This clinical trial studies the following conditions: Relapsed/Refractory Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06090539?
The interventions under investigation include: Mosunetuzumab (DRUG), Rituximab (DRUG), BMS-986458 (DRUG), Glofitamab/Obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT06090539?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090539 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.